• 中文核心期刊要目总览
  • 中国科技核心期刊
  • 中国科学引文数据库(CSCD)
  • 中国科技论文与引文数据库(CSTPCD)
  • 中国学术期刊文摘数据库(CSAD)
  • 中国学术期刊(网络版)(CNKI)
  • 中文科技期刊数据库
  • 万方数据知识服务平台
  • 中国超星期刊域出版平台
  • 国家科技学术期刊开放平台
  • 荷兰文摘与引文数据库(SCOPUS)
  • 日本科学技术振兴机构数据库(JST)
ZHOU Ji-Chao, ZHANG Xiao-Wei. Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases[J]. Chinese Journal of Natural Medicines, 2019, 17(11): 835-841. DOI: 10.1016/S1875-5364(19)30101-3
Citation: ZHOU Ji-Chao, ZHANG Xiao-Wei. Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases[J]. Chinese Journal of Natural Medicines, 2019, 17(11): 835-841. DOI: 10.1016/S1875-5364(19)30101-3

Akkermansia muciniphila: a promising target for the therapy of metabolic syndrome and related diseases

  • Abstract: The probiotic Akkermansia muciniphila (A. muciniphila) is an intestinal bacterium that was first identified in human feces in 2004. Its specialization in mucin degradation makes it a key microorganism that maintains intestinal mucosal barrier function. As an unique representative strain of the phylum Verrucomicrobia that can be cultured in vitro, A. muciniphila is much easier to detect by metagenomic analysis of intestinal flora. In the past few years, A. muciniphila has been getting increasing attention for the positive correlation between its intestinal colonization and host homeostatic metabolism. In this review, we summarize the relationship between A. muciniphila and host health and diseases, especially focusing on metabolic diseases and related mechanisms, as well as the natural food and drug-derived substrates affecting its colonization in the host, expecting to provide evidence and clues for the development of drugs targeting A. muciniphila.

     

/

返回文章
返回